products  impax laboratories inc investor relations media center careers contact home our company our experience our divisions our experience technology innovation products pipeline home » our experience » products an expanding product portfolio impax’s ongoing strategy to invest in rd and to develop highvalue opportunities should continue to provide the potential for growth in the future our products we operate in two segments referred to as impax generics and impax specialty pharma impax generics concentrates its efforts on generic products which are the pharmaceutical and therapeutic equivalents of brandname drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name impax specialty pharma utilizes its specialty sales force to market proprietary branded pharmaceutical products for the treatment of central nervous system cns disorders and other select specialty segments within our generics division we market we currently market over  generic products including but are not limited to budesonide inhalation suspension epinephrine autoinjector wwwepinephrineautoinjectcom generic to adrenaclick® fenofibrate mixed amphetamine salts and oxymorphone hydrochloride impax currently markets its generic products under several labels including impax global pharmaceuticals core pharmaceuticals and lineage therapeutics a list of our currently marketed generic products can be found by visiting global pharmaceuticals httpwwwglobalpharcomproducts core pharmaceuticals httpwwwcorepharmacomourproducts lineage therapeutics httplineagetherapeuticscomlineagetherapeuticsproducts within our specialty pharma division we market treatments for cns disorders to learn more about rytary™ visit wwwrytarycom prescribing information to learn more about zomig® visit wwwzomigcom prescribing information other specialty products to learn more about albenza® visit wwwalbenzacom to learn more about emverm™ visit wwwemvermcom prescribing information top related linkstechnology innovation generics division specialty pharma division phone numberscalifornia locationphone   fax  new jersey locationphone   fax  pennsylvania locationsfort washington phone   fax  taiwan locationphone  copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap home  impax laboratories inc investor relations media center careers contact home our company our experience our divisions learn more improving health through technology impax laboratories is a technologybased specialty pharmaceutical company a leader in the development manufacturing and marketing of specialty prescription pharmaceutical products a dual strategic focus our generics division global pharmaceuticals develops controlledrelease and specialty generics our branded products division impax pharmaceuticals specializes in developing products for the treatment of central nervous system disorders experience is our strength our drug delivery technologies are the foundation of our strength as a company latest news mon  jul impax announces fda approval of its ab rated generic concerta® methylphenidate hydrochloride extendedrelease tablets ciiwed  jul impax announces fda approval and launch of additional strengths of generic focalin xr® dexmethylphenidate hydrochloride extendedrelease capsules ciithu  jun impax to report second quarter  results on august  view all featured generic product epinephrine injection usp autoinjector  mg and  mg authorized generic to adrenaclick® link to prescribing information including all warnings view product featured specialty pharma product rytary carbidopa and levodopa extendedrelease capsules link to prescribing information including all warnings view product copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap home  impax laboratories inc investor relations media center careers contact home our company our experience our divisions learn more improving health through technology impax laboratories is a technologybased specialty pharmaceutical company a leader in the development manufacturing and marketing of specialty prescription pharmaceutical products a dual strategic focus our generics division global pharmaceuticals develops controlledrelease and specialty generics our branded products division impax pharmaceuticals specializes in developing products for the treatment of central nervous system disorders experience is our strength our drug delivery technologies are the foundation of our strength as a company latest news mon  jul impax announces fda approval of its ab rated generic concerta® methylphenidate hydrochloride extendedrelease tablets ciiwed  jul impax announces fda approval and launch of additional strengths of generic focalin xr® dexmethylphenidate hydrochloride extendedrelease capsules ciithu  jun impax to report second quarter  results on august  view all featured generic product epinephrine injection usp autoinjector  mg and  mg authorized generic to adrenaclick® link to prescribing information including all warnings view product featured specialty pharma product rytary carbidopa and levodopa extendedrelease capsules link to prescribing information including all warnings view product copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap home  impax laboratories inc investor relations media center careers contact home our company our experience our divisions learn more improving health through technology impax laboratories is a technologybased specialty pharmaceutical company a leader in the development manufacturing and marketing of specialty prescription pharmaceutical products a dual strategic focus our generics division global pharmaceuticals develops controlledrelease and specialty generics our branded products division impax pharmaceuticals specializes in developing products for the treatment of central nervous system disorders experience is our strength our drug delivery technologies are the foundation of our strength as a company latest news mon  jul impax announces fda approval of its ab rated generic concerta® methylphenidate hydrochloride extendedrelease tablets ciiwed  jul impax announces fda approval and launch of additional strengths of generic focalin xr® dexmethylphenidate hydrochloride extendedrelease capsules ciithu  jun impax to report second quarter  results on august  view all featured generic product epinephrine injection usp autoinjector  mg and  mg authorized generic to adrenaclick® link to prescribing information including all warnings view product featured specialty pharma product rytary carbidopa and levodopa extendedrelease capsules link to prescribing information including all warnings view product copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap careers  impax laboratories inc investor relations media center careers contact home our company our experience our divisions careers working at impax benefits opportunities affirmative action directions home » careers we make a difference – join us at impax we are focused on continuing our history as a successful and profitable company on meeting the challenge of an everchanging healthcare environment and on ensuring a productive and enjoyable place to work join the evergrowing number of employees who are helping to improve healthcare by developing manufacturing and marketing prescription and overthecounter pharmaceutical products using innovative formulations and unique drug delivery technologies impax locations impax headquarters is located in the bay area city of hayward california this is where we perform our development corporate and administrative functions and is home to stateoftheart research and manufacturing facilities impax’s maintains a commercial operations center in philadelphia pa where our packaging quality assurance and shippingreceiving functions reside in a facility located  miles northwest of the city of philadelphia in suburban bucks county pa chalfont resides our sales marketing finance and information technology office and our state of the art distribution center in early  we expanded internationally opening a new stateoftheart manufacturing facility in taiwan this facility increased our manufacturing capacity by  with additional space for future expansion impax is just the smallcompany dynamic environment for you if you value honesty a sense of urgency creativity teamwork achieving results…and if you like to have fun related linksour company facilities copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap contact  impax laboratories inc investor relations media center careers contact home our company our experience our divisions home » contact contact california location mailing address  huntwood ave hayward ca  phone   fax   visitors  genstar rd hayward ca  phone   new jersey location somerset corporate center  somerset corporate boulevard suite  bridgewater nj  telephone   fax   pennsylvania locations fort washington  office center drive fort washington pa  phone   fax   taiwan no  ke dong rd road jhunan science park miaoli county  taiwan phone  to report suspected adverse reactions product complaints or for medical information please contact phone impax  option  phone   option       or email inquiriesimpaxlabscom      or  genstar road hayward ca  attention medical affairs follow link below for impax adverse event and product complaint report form visit httpaeimpaxlabscom you are encouraged to report negative side effects of prescription drugs to the fda visit wwwfdagovmedwatch or call fda for customer service related questions product orders delivery billing account etc please contact phone impax  option      or email customerservicegroupglobalpharcom for investor information email investimpaxlabscom ethics and compliance information us ethics hotline  taiwan in country  wwwimpaxlabsethicspointcom     related linksour company facilities copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap impax laboratories inc  investor relations investor relations  media center  careers  contact homeour companyour experienceour divisionsmedia center investor relations investor relations corporate governance press releases quarterly earnings events and presentations sec filings stock information financial reports analysts investor faq email alerts information request rss feeds investor relationscorporate governancepress releasesquarterly earningsevents and presentationssec filingsstock informationfinancial reportsanalystsinvestor faqemail alertsinformation requestrss feeds home»investor relations our investor relations and communications mission to always communicate with transparency and credibility why invest in impax we are rapidly transforming into a specialty pharmaceutical company and believe it will be a significant driver of our future success in both generics and branded pharmaceuticals why invest in impax we continue to expand our pipeline of product offerings which are aimed to drive growth into the future latest press release rss latest news july   impax announces fda approval of its ab rated generic concerta® methylphenidate hydrochloride extendedrelease tablets cii july   impax announces fda approval and launch of additional strengths of generic focalin xr® dexmethylphenidate hydrochloride extendedrelease capsules cii view all latest event news release webcast investor toolkit email page rss feeds email alerts normal latest events event rss upcoming eventspast events august   impax laboratories second quarter  earnings conference call to access the call through a conference line dial   in the us and   international callers the conference id is a replay of the conference call will be available for seven days shortly after the call to access the replay dial   in the us and   international callers the access code for the replay is  webcast view the press release  view presentation  june   goldman sachs th annual global healthcare conference webcast view the press release  view presentation  may   ubs global healthcare conference webcast view the press release  view presentation  view all related links products and pipeline leadership contact investor toolkit email page rss feeds email alerts copyright   impax laboratories inc all rights reserved sitemap  legal and copyright disclaimer name first name is required email email is required comments enter text   enter the code shown above  invalid powered by q inc  our company  impax laboratories inc investor relations media center careers contact home our company our experience our divisions our company our story future directions leadership business development corporate responsibility facilities new cpsia product list home » our company dedicated to pharmaceutical innovation impax laboratories is a technologybased specialty pharmaceutical company utilizing our core competency in drug delivery and formulation expertise we have a balanced business model consisting of a successful generic business targeting highvalue solid oral and alternative dosage form abbreviated new drug applications anda and a branded business currently focused on internally developing central nervous system cns products where we can deliver meaningful patient benefits and develop strong intellectual property positions corporate headquarters mailing address  huntwood ave hayward ca    visitors  genstar rd hayward ca    research areas we have a dual strategic focus that stretches across our generic division and our branded division our generic business strategy is focused on targeting highvalue solid oral and alternative dosage form andas that are difficult to develop and that bring sustainable profitability we explore a broad range of therapeutic areas that have technically challenging drug delivery mechanisms or other niches including products with the potential for six months of exclusivity for being firsttofile or firsttomarket our brand business strategy is focused on cns disorders we are applying our formulation expertise and clinical development experience to develop differentiated modified or controlledrelease versions of currently marketed drug products growth strategy we are focused on adding to the growth our own innovations will bring with acquisitions of external growth opportunities our business development activities are focusing on technologies in new dosage forms or products or companies where our core competency in creative technologies and methods can result in synergies from further technical innovation these could be in either generic or proprietary opportunities complementary to our own creative efforts related linkstechnology innovation products pipeline impax labs factat impax laboratories we are following a growthoriented strategy to become a leader in the development manufacturing and marketing of specialty prescription pharmaceutical products  copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap our divisions  impax laboratories inc investor relations media center careers contact home our company our experience our divisions our divisions generics division specialty pharma division home » our divisions our two corporate divisions we have two platforms that offer the right balance for future growth our vision is to target key areas of growth that reflect both our internal strengths and a strong market treatment or product need our generics division in the generic pharmaceuticals market we utilize our core competency in drug delivery expertise and formulation development to target highvalue solid oral and alternative dosage form adf andas that are difficult to develop and that bring sustainable profitability this includes products with the potential for six months of exclusivity for being firsttofile or products that are difficult to develop externally we are aggressively looking at strategic alliances and collaboration agreements as well as opportunities to acquire products technologies or companies with strategic value mainly in the alternative dosage area such as injectables creams and ointments inhalers or patches continue reading specialty pharma division in the brand name pharmaceuticals market we are focused on internally developing central nervous system cns disorder products where we can deliver meaningful patient benefits and develop strong intellectual property positions we believe the successful development of our brand business is critical to our future growth as brand products provide longer product life cycles with the potential for higher profits our strategic initiatives for growth include continuing our internal rd focus on neurology by building a strong pipeline in addition we are searching for external growth opportunities through partnerships and ma in cns continue reading related linksfuture directions our experience impax labs factat impax laboratories we are following a growthoriented strategy to become a leader in the development manufacturing and marketing of specialty prescription pharmaceutical products  copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap generics division  impax laboratories inc investor relations media center careers contact home our company our experience our divisions our divisions generics division specialty pharma division home » our divisions » generics division impax generics our generics division view website impax has developed a portfolio of generic pharmaceuticals through the internal filing of abbreviated new drug applications andas and through partnerships on alternative dosage form products our generic product development strategy is based on a combination of speed to filing and a legal strategy primarily predicated upon noninfringement of established brand name pharmaceuticals we are focused on targeting highvalue solid oral and alternative dosage form andas that are difficult to develop and that bring sustainable profitability global’s multisource product line consists of a growing range of solid oral and alternative dosage form prescription pharmaceuticals distributed primarily through drug wholesalers distributors warehousing chains and managed healthcare organizations the organization continues to invest in order to provide the highest level of research and development manufacturing and customer service our quality assurance team works closely with our suppliers to ensure purity consistency and quality of products and we strive to bring value to our customers with innovative products in key therapeutic areas we have a dedicated team of experienced professionals handling customer orders and inquiries that work to not only meet the expectations of our customers but consistently deliver beyond expectations every member of our team is committed to the success and profitability of our customers we have set the highest standards for our products services and people and are proud of the organization we are building we develop manufacture sell and distribute generic pharmaceutical products primarily through three sales channels product sales channel for generic pharmaceutical prescription products we sell directly to wholesalers large retail drug chains mass merchandisers and mailorder pharmacies rx partner sales channel for generic prescription products sold through unrelated thirdparty pharmaceutical entities pursuant to alliance agreements otc partner sales channel for sales of generic pharmaceutical otc products sold through unrelated thirdparty pharmaceutical entities pursuant to alliance agreements product development strategy our generic product development strategy is based on two opportunities weve identified in the generic pharmaceutical marketplace controlledrelease generic products through our controlledrelease drug delivery technologies and formulation skills we develop bioequivalent versions of selected brand name pharmaceuticals controlledrelease pharmaceuticals generally have technically challenging drug delivery requirements we employ our proprietary processes and formulation expertise to develop products that reproduce the brand name product’s physiological characteristics but do not infringe upon the brand product’s patents specialty generic products products that present one or more competitive barriers to entry such as difficulty sourcing raw material complex formulation or development characteristics or special handling requirements our products we currently manufacture and market  generic pharmaceutical products which represent dosage variations of  different pharmaceutical compounds through our generics division another five of our generic pharmaceutical products representing dosage variations of two different pharmaceutical compounds are marketed by our alliance agreement partners our pipeline we currently have more than  abbreviated new drug applications anda pending at the fda we are also working on a number of products in various stages of development for which applications have not yet been filed top related linksfuture directions technology innovation pipeline generics division factglobal pharmaceuticals currently markets  generic pharmaceutical products which represent dosage variations of  different pharmaceutical compounds copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap impax laboratories inc issues voluntary nationwide recall for one lot of lamotrigine orally disintegrating tablet  mg due to the potential for  mg blister cards being packaged in  mg containers skip to main page content skip to search skip to topics menu skip to common links hhs us department of health and human services us food and drug administration a to z index follow fda en español search fda submit search safety home safety recalls market withdrawals  safety alerts company announcement when a company announces a recall market withdrawal or safety alert the fda posts the companys announcement as a public service fda does not endorse either the product or the company impax laboratories inc issues voluntary nationwide recall for one lot of lamotrigine orally disintegrating tablet  mg due to the potential for  mg blister cards being packaged in  mg containers share tweet linkedin pin it more sharing options linkedin pin it email print for immediate release august   contact consumersstericyclemediamark donohue announcement view product photos impax laboratories inc nasdaq ipxl announced today that the company had issued a voluntary nationwide retail level recall on august   for one lot of lamotrigine orally disintegrating tablet odt  mg the company is issuing this press release to provide further heightened awareness of this recall and to provide instructions to consumers pharmacists and wholesalers in possession of the affected product details related to the recalled product are set forth belowndc numberblister packlot numberunitofuse blister packs a  count blister card contained in a single plastic shellpack may contain  mg product instead of  mg product each blister card within the unitofuse blister pack is properly labeled as  mg odt however the plastic shell pack containing the  mg blister cards is labeled as  mg odt shellpacks from the affected lot may contain  mg odt instead of  mg odt and as a result it is possible that consumers could take less than their intended lamotrigine doselamotrigine is indicated for the treatment of epilepsy or bipolar disorders it is important for consumers to take the dose of lamotrigine prescribed by their physicians a reduction in dose may lead to reduced therapeutic effects of lamotrigine and reemergence of epilepsy or bipolar disorder symptomsthe affected lot was distributed between june   and august   to wholesale distributors and retail pharmacies nationwide the lot number can be found on the side of the manufacturer’s carton as well as on the blister cards within the unitofuse blister packs lamotrigine odt  mg tablets are offwhite to white circular tablets approximately  mm in diameter debossed with “wpi” on one side and “”on the other supplied in blisters of  ndc  and in cartons of  ndc consumers are being asked to carefully inspect their medication if they have the affected lot or any questions or concerns regarding this recall they should contact stericycle at  monday through friday  am through  pm est consumers who are unsure if they have the affected lot number or have any concerns about their product should consult their pharmacy or health care professionalpharmacists and wholesalers are being asked to check their inventories for the affected lot segregate any material from the lot and to then contact stericycle at  for instructions on product return pharmacies that received the affected lot will receive a copy of this press release with their recall notification information to be prominently posted in the pharmacy areaonlinewwwfdagovmedwatchreporthtmregular mail use postagepaid preaddressed form fda  available at wwwfdagovmedwatchgetformshtm mail to address on the preaddressed formfax fdathis voluntary recall is being made with the knowledge of the us food and drug administration about impax laboratories incimpax laboratories inc impax is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlledrelease and specialty generics in addition to the development of central nervous system disorder branded products impax markets its generic products through its impax generics division and markets its branded products through the impax specialty pharma division additionally where strategically appropriate impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies such as injectables nasal sprays inhalers patches creams and ointments  follow fda follow usfda on twitter follow fda on facebook follow fdarecalls on twitter recent recalled product photos on fdas flickr photostream product photos more in recalls market withdrawals  safety alerts archive for recalls market withdrawals  safety alerts    enforcement reports pending recalls archived enforcement reports industry guidance major product recalls dkh cheese recalls listeria monocytogenes contamination frozen vegetable products listeria monocytogenes industry resources for recalls undeclared peanut from cumin ingredient recalls sunland nut and seed product recalls page last updated  note if you need help accessing information in different file formats see instructions for downloading viewers and players language assistance available español    tiếng việt  한국어  tagalog  русский  العربية  kreyòl ayisyen  français  polski  português  italiano  deutsch    فارسی  english impax laboratories inc ndaqipxl has been upgraded from underweight to neutral in a report by piper jaffray today headlines business technology economy personal finance menuheadlines business technology economy personal finance dont miss peet’s buys majority stake in another coffee chain walgreen records q loss as expected ebay plans to spin off paypal tibco taken private by vista equity for  billion athlon energy athl up big on buyout news dave  buster’s ipo terms set  per share home  investing  impax laboratories inc ndaqipxl has been upgraded from underweight to neutral in a report by piper jaffray today impax laboratories inc ndaqipxl has been upgraded from underweight to neutral in a report by piper jaffray today by al wild updated july   piper jaffray has upgraded impax laboratories inc ndaqipxl from underweight to neutral in a report released on  previously on friday june   cantor fitzgerald reported on impax laboratories inc ndaqipxl raised the target price from  to  at the time this indicated a possible upside of  yesterday impax laboratories inc ndaqipxl traded  lower at  the company’s day moving average is  and its day moving average is  the last closing price is up  from the day moving average compared to the sp  which has increased  over the same time  shares of the stock were exchanged up from an average trading volume of  see chart below impax laboratories inc has a  week low of  and a  week high of  the company’s market cap is currently  in addition to piper jaffray reporting its target price a total of  brokers have issued a report on the stock the consensus target price is  with  brokers rating the stock a strong buy  brokers rating the stock a buy  brokers rating the stock a hold  brokers rating the stock a underperform and finally  brokers rating the stock a sell general information about impax laboratories inc ndaqipxl impax laboratories inc is a specialty pharmaceutical company the company is engaged in the development manufacture and marketing of bioequivalent pharmaceutical products generics in addition to the development and marketing of branded products its segments include impax generics and impax specialty pharma the impax generics segment is focused on the development manufacture sale and distribution of its generic products which are the pharmaceutical and therapeutic equivalents of brandname drug products and are marketed under their established drug names the impax specialty pharma segment is engaged in the promotion sale and distribution of several branded products including its branded pharmaceutical product rytary an extended release oral capsule formulation of carbidopalevodopa for the treatment of parkinsons disease postencephalitic parkinsonism and parkinsonism and zomig zolmitriptan products indicated for the treatment of migraine headaches receive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with marketbeatcoms free daily email newsletter leave a reply cancel reply your email address will not be published required fields are marked comment name  email  website more news a statement released earlier today by whitman howard about dairy crest group plc londcg maintains the target price at gbx stating a potential upside of  micro focus international plc lonmcro target price raised to gbx issued a report today by citigroup having a price of gbx micro a statement released earlier today by northland capital about ascent resources plc lonast holds the target price at gbx yesterday ascent resources plc lonast traded just eat lonje has been reiterated to buy in a statement by shore capital earlier today shore capital has reiterated just eat peel hunt recorded bloomsbury publishing plc lonbmy renewing its target price at gbx today having a price of gbx bloomsbury a statement released earlier today by imperial capital about wpx energy tsewpx raises the target price to  yesterday wpx energy tsewpx traded  premier african minerals lonprem has been reiterated to speculative buy in a statement by northland capital earlier today northland capital has reiterated premier african bilby plc lonbilb target price raised to gbx reported today by northland capital boasting a price of gbx bilby exane bnp paribas reiterated wizz air holdings plc lonwizz to neutral in a report released earlier today exane bnp paribas has reiterated wizz bt group plc lonbta target bumped down to gbx released a report earlier today by exane bnp paribas having a price of gbx bt about breaking finance news contributors contact privacy policy copyright   breaking finance news impax laboratories inc ndaqipxl has been upgraded from underweight to neutral in a report by piper jaffray today headlines business technology economy personal finance menuheadlines business technology economy personal finance dont miss peet’s buys majority stake in another coffee chain walgreen records q loss as expected ebay plans to spin off paypal tibco taken private by vista equity for  billion athlon energy athl up big on buyout news dave  buster’s ipo terms set  per share home  investing  impax laboratories inc ndaqipxl has been upgraded from underweight to neutral in a report by piper jaffray today impax laboratories inc ndaqipxl has been upgraded from underweight to neutral in a report by piper jaffray today by al wild updated july   piper jaffray has upgraded impax laboratories inc ndaqipxl from underweight to neutral in a report released on  previously on friday june   cantor fitzgerald reported on impax laboratories inc ndaqipxl raised the target price from  to  at the time this indicated a possible upside of  yesterday impax laboratories inc ndaqipxl traded  lower at  the company’s day moving average is  and its day moving average is  the last closing price is up  from the day moving average compared to the sp  which has increased  over the same time  shares of the stock were exchanged up from an average trading volume of  see chart below impax laboratories inc has a  week low of  and a  week high of  the company’s market cap is currently  in addition to piper jaffray reporting its target price a total of  brokers have issued a report on the stock the consensus target price is  with  brokers rating the stock a strong buy  brokers rating the stock a buy  brokers rating the stock a hold  brokers rating the stock a underperform and finally  brokers rating the stock a sell general information about impax laboratories inc ndaqipxl impax laboratories inc is a specialty pharmaceutical company the company is engaged in the development manufacture and marketing of bioequivalent pharmaceutical products generics in addition to the development and marketing of branded products its segments include impax generics and impax specialty pharma the impax generics segment is focused on the development manufacture sale and distribution of its generic products which are the pharmaceutical and therapeutic equivalents of brandname drug products and are marketed under their established drug names the impax specialty pharma segment is engaged in the promotion sale and distribution of several branded products including its branded pharmaceutical product rytary an extended release oral capsule formulation of carbidopalevodopa for the treatment of parkinsons disease postencephalitic parkinsonism and parkinsonism and zomig zolmitriptan products indicated for the treatment of migraine headaches receive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with marketbeatcoms free daily email newsletter leave a reply cancel reply your email address will not be published required fields are marked comment name  email  website more news a statement released earlier today by whitman howard about dairy crest group plc londcg maintains the target price at gbx stating a potential upside of  micro focus international plc lonmcro target price raised to gbx issued a report today by citigroup having a price of gbx micro a statement released earlier today by northland capital about ascent resources plc lonast holds the target price at gbx yesterday ascent resources plc lonast traded just eat lonje has been reiterated to buy in a statement by shore capital earlier today shore capital has reiterated just eat peel hunt recorded bloomsbury publishing plc lonbmy renewing its target price at gbx today having a price of gbx bloomsbury a statement released earlier today by imperial capital about wpx energy tsewpx raises the target price to  yesterday wpx energy tsewpx traded  premier african minerals lonprem has been reiterated to speculative buy in a statement by northland capital earlier today northland capital has reiterated premier african bilby plc lonbilb target price raised to gbx reported today by northland capital boasting a price of gbx bilby exane bnp paribas reiterated wizz air holdings plc lonwizz to neutral in a report released earlier today exane bnp paribas has reiterated wizz bt group plc lonbta target bumped down to gbx released a report earlier today by exane bnp paribas having a price of gbx bt about breaking finance news contributors contact privacy policy copyright   breaking finance news bmo capital keeps  tp on merck  company mrk keeps buy rating impax laboratories ipxl sellers decreased by  their shorts  bibey post trending stock news penny stock news market news stock news bmo capital keeps  tp on merck  company mrk keeps “buy” rating impax laboratories ipxl sellers decreased by  their shorts july    by louis casey among  analysts covering merck  co inc nysemrk  have buy rating  sell and  hold therefore  are positive merck  co inc has  highest and  lowest target ’s average target is  above currents  stock price merck  co inc had  analyst reports since august   according to sratingsintel the stock has “buy” rating by bryan garnier  cie on friday january  jefferies maintained the stock with “hold” rating in thursday july  report the firm has “market perform” rating by cowen  co given on wednesday april  the rating was maintained by credit suisse on monday may  with “neutral” the stock of merck  co inc nysemrk has “sell” rating given on tuesday july  by bmo capital markets the firm has “buy” rating given on monday june  by bmo capital markets on thursday january  the stock rating was upgraded by guggenheim to “buy” the firm has “market perform” rating by bmo capital markets given on monday july  the firm has “sell” rating by jefferies given on monday july  the rating was maintained by jefferies on tuesday march  with “hold” impax laboratories incorporated nasdaqipxl had a decrease of  in short interest ipxl’s si was m shares in july as released by finra its down  from m shares previously with m avg volume  days are for impax laboratories incorporated nasdaqipxl’s short sellers to cover ipxl’s short positions the si to impax laboratories incorporated’s float is  it closed at  lastly it is down  since july   and is downtrending it has underperformed by  the sp merck  co inc is a global healthcare company the company has market cap of  billion the firm offers health solutions through its prescription medicines vaccines biologic therapies and animal health products it has a  pe ratio it operates through four divisions pharmaceutical animal health healthcare services and alliances about  shares traded merck  co inc nysemrk has risen  since july   and is uptrending it has outperformed by  the sp analysts await merck  co inc nysemrk to report earnings on july  before the open they expect  eps down  or  from last year’s  per share mrk’s profit will be  billion for  pe if the  eps becomes a reality after  actual eps reported by merck  co inc for the previous quarter wall street now forecasts  eps growth investors sentiment increased to  in  q its up  from  in q it increased as  investors sold merck  co inc shares while  reduced holdings  funds opened positions while  raised stakes  billion shares or  more from  billion shares in q were reported regions fincl reported  stake eqis management has invested  in merck  co inc nysemrk sadoff invest llc accumulated  or  shares lynch  associate in holds  or  shares citadel advsr limited liability corp accumulated  shares or  of the stock cullen management lc reported  in merck  co inc nysemrk dimensional fund advsrs ltd partnership reported m shares brown brothers harriman and accumulated  or  shares zwj inv counsel holds  or  shares in its portfolio lsv asset management reported  million shares state bank of the west has  invested in merck  co inc nysemrk for  shares sentinel asset management inc reported  shares or  of all its holdings pzena invest mgmt ltd liability co invested in  or  million shares  are owned by bangor commercial bank manchester cap limited co holds  or  shares impax laboratories inc is a specialty pharmaceutical company the company has market cap of  billion the firm is engaged in the development manufacture and marketing of bioequivalent pharmaceutical products  in addition to the development and marketing of branded products it currently has negative earnings the company’s divisions include impax generics and impax specialty pharma investors sentiment decreased to  in  q its down  from  in q it is negative as  investors sold impax laboratories inc shares while  reduced holdings  funds opened positions while  raised stakes  million shares or  less from  million shares in q were reported putnam invs ltd liability co reported  shares rhumbline advisers has  shares ftb advisors inc holds  or  shares zurcher kantonalbank zurich cantonalbank reported  shares gru one trading l p reported  shares connecticutbased point asset limited partnership has invested  in impax laboratories inc nasdaqipxl tekla ltd stated it has  of its portfolio in impax laboratories inc nasdaqipxl panagora asset management incorporated holds  in impax laboratories inc nasdaqipxl or  shares franklin reported m shares gemmer asset mngmt limited com holds  or  shares morgan stanley holds  of its portfolio in impax laboratories inc nasdaqipxl for  shares northwestern mutual wealth mngmt has  invested in impax laboratories inc nasdaqipxl envestnet asset management holds  shares cubist systematic strategies ltd liability accumulated  shares lsv asset mngmt owns  shares for  of their portfolio by louis casey echostar corporationreceive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with our free daily email newsletter free newsletter enter your email address below to get the latest news and analysts ratings for your stocks with our free daily email newsletter recent posts  eps expected for international seaways insw  analysts are bullish sciquest inc sqi last week alpha and omega semiconductor ltd aosl analysts see  eps udr udr’s sentiment is  eps for xenia hotels  resorts xhr expected at  maxim integrated products mxim has  sentiment analysts see  eps for virtusa vrtu gilder gagnon howe  co has increased its servicenow com usd now holding tidewater inc tdw eps estimated at  howard hughes medical institute has trimmed visa v holding transdigm group tdg analysts see  eps howard hughes medical institute increased pioneer nat res co pxd position by  dream industrial real estate invest trst dirun analysts see  eps daiwa securities group has increased by  its marvell technology group mrvl position  eps expected for spectrum pharmaceuticals inc sppi strategy asset managers lowered by  its american intl group aig holding becker capital management has increased national oilwell varco nov holding by  million fossil group fosl’s sentiment is   eps expected for nrg energy nrg huntington national bank has boosted its sandridge mississippian trust sdr position  copyright  bibey post inc  bibeypostcom       about  our team  contact bmo capital keeps  tp on merck  company mrk keeps buy rating impax laboratories ipxl sellers decreased by  their shorts  bibey post trending stock news penny stock news market news stock news bmo capital keeps  tp on merck  company mrk keeps “buy” rating impax laboratories ipxl sellers decreased by  their shorts july    by louis casey among  analysts covering merck  co inc nysemrk  have buy rating  sell and  hold therefore  are positive merck  co inc has  highest and  lowest target ’s average target is  above currents  stock price merck  co inc had  analyst reports since august   according to sratingsintel the stock has “buy” rating by bryan garnier  cie on friday january  jefferies maintained the stock with “hold” rating in thursday july  report the firm has “market perform” rating by cowen  co given on wednesday april  the rating was maintained by credit suisse on monday may  with “neutral” the stock of merck  co inc nysemrk has “sell” rating given on tuesday july  by bmo capital markets the firm has “buy” rating given on monday june  by bmo capital markets on thursday january  the stock rating was upgraded by guggenheim to “buy” the firm has “market perform” rating by bmo capital markets given on monday july  the firm has “sell” rating by jefferies given on monday july  the rating was maintained by jefferies on tuesday march  with “hold” impax laboratories incorporated nasdaqipxl had a decrease of  in short interest ipxl’s si was m shares in july as released by finra its down  from m shares previously with m avg volume  days are for impax laboratories incorporated nasdaqipxl’s short sellers to cover ipxl’s short positions the si to impax laboratories incorporated’s float is  it closed at  lastly it is down  since july   and is downtrending it has underperformed by  the sp merck  co inc is a global healthcare company the company has market cap of  billion the firm offers health solutions through its prescription medicines vaccines biologic therapies and animal health products it has a  pe ratio it operates through four divisions pharmaceutical animal health healthcare services and alliances about  shares traded merck  co inc nysemrk has risen  since july   and is uptrending it has outperformed by  the sp analysts await merck  co inc nysemrk to report earnings on july  before the open they expect  eps down  or  from last year’s  per share mrk’s profit will be  billion for  pe if the  eps becomes a reality after  actual eps reported by merck  co inc for the previous quarter wall street now forecasts  eps growth investors sentiment increased to  in  q its up  from  in q it increased as  investors sold merck  co inc shares while  reduced holdings  funds opened positions while  raised stakes  billion shares or  more from  billion shares in q were reported regions fincl reported  stake eqis management has invested  in merck  co inc nysemrk sadoff invest llc accumulated  or  shares lynch  associate in holds  or  shares citadel advsr limited liability corp accumulated  shares or  of the stock cullen management lc reported  in merck  co inc nysemrk dimensional fund advsrs ltd partnership reported m shares brown brothers harriman and accumulated  or  shares zwj inv counsel holds  or  shares in its portfolio lsv asset management reported  million shares state bank of the west has  invested in merck  co inc nysemrk for  shares sentinel asset management inc reported  shares or  of all its holdings pzena invest mgmt ltd liability co invested in  or  million shares  are owned by bangor commercial bank manchester cap limited co holds  or  shares impax laboratories inc is a specialty pharmaceutical company the company has market cap of  billion the firm is engaged in the development manufacture and marketing of bioequivalent pharmaceutical products  in addition to the development and marketing of branded products it currently has negative earnings the company’s divisions include impax generics and impax specialty pharma investors sentiment decreased to  in  q its down  from  in q it is negative as  investors sold impax laboratories inc shares while  reduced holdings  funds opened positions while  raised stakes  million shares or  less from  million shares in q were reported putnam invs ltd liability co reported  shares rhumbline advisers has  shares ftb advisors inc holds  or  shares zurcher kantonalbank zurich cantonalbank reported  shares gru one trading l p reported  shares connecticutbased point asset limited partnership has invested  in impax laboratories inc nasdaqipxl tekla ltd stated it has  of its portfolio in impax laboratories inc nasdaqipxl panagora asset management incorporated holds  in impax laboratories inc nasdaqipxl or  shares franklin reported m shares gemmer asset mngmt limited com holds  or  shares morgan stanley holds  of its portfolio in impax laboratories inc nasdaqipxl for  shares northwestern mutual wealth mngmt has  invested in impax laboratories inc nasdaqipxl envestnet asset management holds  shares cubist systematic strategies ltd liability accumulated  shares lsv asset mngmt owns  shares for  of their portfolio by louis casey echostar corporationreceive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with our free daily email newsletter free newsletter enter your email address below to get the latest news and analysts ratings for your stocks with our free daily email newsletter recent posts  eps expected for international seaways insw  analysts are bullish sciquest inc sqi last week alpha and omega semiconductor ltd aosl analysts see  eps udr udr’s sentiment is  eps for xenia hotels  resorts xhr expected at  maxim integrated products mxim has  sentiment analysts see  eps for virtusa vrtu gilder gagnon howe  co has increased its servicenow com usd now holding tidewater inc tdw eps estimated at  howard hughes medical institute has trimmed visa v holding transdigm group tdg analysts see  eps howard hughes medical institute increased pioneer nat res co pxd position by  dream industrial real estate invest trst dirun analysts see  eps daiwa securities group has increased by  its marvell technology group mrvl position  eps expected for spectrum pharmaceuticals inc sppi strategy asset managers lowered by  its american intl group aig holding becker capital management has increased national oilwell varco nov holding by  million fossil group fosl’s sentiment is   eps expected for nrg energy nrg huntington national bank has boosted its sandridge mississippian trust sdr position  copyright  bibey post inc  bibeypostcom       about  our team  contact impax laboratories inc nasdaqipxl rating reiterated by royal bank of canada casa nossos contatos lazertecnologia vendredi  juillet   finanças entretenimento tecnologia esportes global medicina nacional ﻿ tecnologia impax laboratories inc nasdaqipxl rating reiterated by royal bank of canada juillet   · brennan troyen a had sold  shares worth m on tuesday march  about shares traded a h belo corporation ahc has risen  since july   and is uptrending it has outperformed by  the sp the return on investment roi ratio of impax laboratories inc nasdaqipxl  have buy rating  sell and  hold therefore  are positive the stock carved out a week low down at  the stock closing price is now trading downward to its  day moving average with change of  tumbled to its  day moving average with figure of  and above its  day moving average with value illegal activity notice mason street advisors llc has  stake in impax laboratories inccantor fitzgerald initiated coverage with a overweight rating ipxl are stable and safe compared to the lower market capitalization companies a total number of  analysts provided estimations over revenues finally bmo capital markets restated a hold rating and set a  target price on shares of impax laboratories in a report on friday june rd goldman sachs upgraded the stock to neutral rating in tuesday september  reportnow the shares of impax laboratories incon  michael nestor insider sold  with an average share price of  per share and the total transaction amounting to  ipxl now has a value of  while the companys  week low is at  the shares dropped to the  week low on impax laboratories inc nasdaqipxl has now crossed into technical strength  watch the technical oscillators for momentum gaps during the same period in the previous year the business posted  earnings per share janney capital initiated impax laboratories inc nasdaqipxl on wednesday december  with neutral ratinghow active are impax laboratories inc legato capital management boosted its stake in impax laboratories by  in the q the firm is engaged in the development manufacture and marketing of bioequivalent pharmaceutical products in addition to the development and marketing of branded products a negative earnings surprise will usually result in a decline in share priceapproval of our abrated generic version of concerta further demonstrates the capabilities of impaxs rd organization said paul bisaro president and chief executive officer of impax stock has got outperform rating from  analyst s whereas last month  analyst s have given outperform rating sold all  reduced  increased  new position  vanguard stated it has  million shares  impax laboratories inc had its market perform rating reiterated by analysts at leerink swann the stock rose  or  reaching  per share tfs cap reported  shares the californiabased lyon street capital llc has invested  in the stock moreover bank  trust of america corp de has  invested in impax laboratories inc nasdaqipxl for  shares franklin incorporated reported  stake kcg holds  in impax laboratories inc nasdaqipxl or  shares  impax laboratories inc was downgraded to  by analysts at piper jaffrayabout  million shares traded or  up from the average it has underperformed by  the spinvestors sentiment increased to  in q a number of institutional investors have recently bought and sold shares of the companythese funds have also shifted positions in ipxl morgan stanley owns  shares over the last three months the shares of the company have changed  and performed  over the last six months ny state common retirement fund holds  shares invesco holds  of its portfolio in rignet inc nasdaqrnet for  shares quantitative invest management ltd liability accumulated  shares welch forbes ltd company has  shares for  of their portfolio  were reported by cornerstone hldg lc blackrock fund advsrs has invested  in rignet inc nasdaqrnet the minnesotabased punch  associates investment management inc has invested  in the stock shares for  million were sold by sussman andrew enable midstream partners had  analyst reports since july   according to sratingsintel the firm earned buy rating on tuesday october  by btig research the firm has hold rating by deutsche bank given on wednesday august  sidoti initiated the shares of rnet in report on monday august  with buy rating notícias recomendadas  juillet  les édulcorants artificiels augmentent le risque dobésité lexperte en exercice et en sciences nutritives allison sylvetskymeni citée par live science  essaye de faire la part des choses  juillet  ancelotti no trajimos a james para reemplazar a nadie james rodríguez hizo parte de la delegación de  jugadores convocados por el técnico carlo ancelotti para el denominado audi summer tour   juillet  you wont believe this love island conspiracy theory about marcel sommerville in other love island news onoffonoff and now official couple olivia and chris declared their love for each other and in tuesday nights show the couple come to blows after she walks away from him while hes speaking to her   juillet  he equipment services inc hees stock price increases today illegal activity warning this news story was first reported by bnb daily and is the sole property of of bnb daily granite inv limited liability company has invested  of its portfolio in he equipment services inc  juillet  passe darmes entre macron et larmée  bfmtv choisit son camp une expression publique qui a fortement déplu à emmanuel macron  président de la république et par le fait chef des armées en retour ceux du président macron ont été durs dans la soirée du  juillet au ministère à bon entendeur  juillet  donetsk separatist leader declares new state in eastern ukraine ukraine has demonstrated its current and future incapability of providing peace and prosperity to its residents  the declaration said  juillet  willis on biletnikoff award preseason watch list ross is coming off his junior campaign when he led the buffs in receptions with  a total that ranked fourth in the pac the award is presented each year to the top wide receiver in college football  juillet  kenny rogers tribute concert will feature his final performance with dolly parton tennessean reports that tickets will go on sale  at  am through ticketmaster or the bridgestone arenas box office  rogers said the concert would prove a moving experience for us standing on that stage together for one last time  juillet  real madrid complete signing of euro u star — done deal i am truly grateful to all of the people in the verdiblanco family for having developed me as a player and as a person so far the moves that have been made hint at a more holistic approach to transfers  juillet  lopération de mccain retarde la réforme de santé de trump en   comtés américains sur  ne proposeront aucune assurance dans le cadre dobamacare  et sils sont opposés à lobamacare  ils se disent insatisfaits du contenu de la réforme  juillet  julia hurricane hawkins  sets new record in the meter dash the insane thing is hawkins only started racing track past year when she went to the state olympics in lake charles age is but a number and someone who lives by this is yearold greatgrandmother julia hurricane hawkins  juillet  nike nba jerseys for  season unveiled it not only matches nikes commitment to sustainability but it wicks sweat  faster than current uniforms and dries  faster two more colors will be unveiled during the season including the classic a colorway that plays on the teams pasts siganos juntese à conversa we are pleased to provide this opportunity to share information experiences and observations about whats in the news some of the comments may be reprinted elsewhere in the site or in the newspaper thank you for taking the time to offer your thoughts tendências em lazertecnologiacom crônica da notícia high dose vitamin d no advantage in preventing pediatric viral infections the primary outcome was the number of laboratoryconfirmed viral urtis over the winter months disclosures  agliplay and maguire report no relevant financial disclosures ryan murphy reveals final clue before ahs title unveiling in another instagram post  murphy gave followers a look at a picture showing twisty the clown in all his menacing glory well maybe it will all make sense when ryan unveils the series title on thursday as promised  suspected norovirus causes chipotle to close sterling location the move follows a series of foodborneillness outbreaks in  that sent chipotles sales and stock price plunging in one particular case a patron reported needing two hospitalizations due to the illnesses dominion diamond corp ddc stock closed at  finally norges bank acquired a new position in shares of dominion diamond corporation during the fourth quarter worth  the stock of dominion diamond corp nyseddc earned overweight rating by barclays capital on wednesday september  biglia il milan una scelta sportiva nessun problema con la lazio per capire il pensiero della curva nord basta aspettare il primo allenamento di lucas biglia sul campo vincenzo montella avrà finalmente il suo nuovo playmaker  ménages sur  ne payent pas dimpôts sur le revenu une performance qui nest pas sans lien avec le ras le bol fiscal  exprimé par les français à lépoque en   des ménages étaient imposables ils ne sont aujourdhui plus que  frontier airlines returning to tulsa as part of nationwide expansion the airline also announced it would return to will rogers airport in oklahoma city the oklahoman reported frontiers flights will increase from  to  the number of nonstop destinations served at tia honolulu mayor pushing bill requiring sprinklers now buildings on oahu constructed before   such as the one that caught fire on friday  can go without sprinkler systems a sprinkler system would have confined the blaze to the unit where it started honolulu fire chief manuel neves said life is strange before the storm trailer focuses on chloe and rachel burch and lead writer zak gariss discuss what it took to create the story of chloe before she met max the upcoming life is strange sequel life is strange before the storm  has received a new trailer furious bbc listeners condemn radio  presenter after disgraceful johanna konta interview johanna konta says her ability to learn from previous defeats has been key in her rise up the world rankings into fourth spot but ive lived half my life here now almost so im a british citizen and im incredibly proud to represent great britain tendências glu mobile nasdaqgluu earns news impact score of lebanon plans military operation at syrian border amnesty international dans le collimateur des autorités turques australias membership will provide great boost to international solar alliance pm modi hosts netherlands beat norway in womens euro opener mercato man city bony va partir vatican childrens hospital officials tried for embezzlement american capital agency corp bitcoin price is the storm over pence wh fully supports mcconnell push for ocare repeal without replace baby who contracted deadly virus from kiss dies antarctic iceberg a on the big move dominicanos expresan apoyo a la marcha verde dentro y fuera del país xi pledges unremitting efforts for middle east peace federer derruba croata é octa em wimbledon e bate recorde lazertecnologiacom no social   ﻿ casa nossos contatos direito autoral   — lazertecnologiacom todos os direitos reservados impax laboratories  wikipedia impax laboratories from wikipedia the free encyclopedia jump to navigation search impax laboratories inc traded as nasdaq ipxl sp  component founded   founder charles hsiao phd and chungchiang hsu phd headquarters hayward california number of locations manufacturing plants in hayward ca middlesex nj and taiwan products generic and specialty pharmaceuticals revenue est  million  number of employees over  employees worldwide divisions generics and specialty pharma divisions website impaxlabscom impax laboratories inc is a publicly traded company listed on the nasdaq stock market llc under the symbol “ipxl” is a specialty pharmaceutical company focused on developing manufacturing and marketing generic and branded products the company is headquartered in hayward california and has additional offices and facilities in new jersey pennsylvania and taiwan roc contents  history  mergers and acquisitions  operations  regulatory and litigation  references  external links historyedit the company’s predecessor entity privately held impax pharmaceuticals inc was founded in  publicly traded global pharmaceutical corporation and impax pharmaceuticals inc completed a reverse merger forming impax laboratories inc on december   the merger combined the advanced drug delivery systems developed by impax pharmaceuticals through its research and development capabilities with global pharmaceutical’s sales marketing and distribution capabilities mergers and acquisitionsedit in march  impax completed its acquisition of tower holdings inc including operating subsidiaries corepharma llc and amedra pharmaceuticals llc including its adrenaclick epinephrine autoinjector and lineage therapeutics inc in connection with the closing of the acquisition impax reshaped the operating and reporting structure of its two divisions into impax generics and impax specialty pharma in june  the company acquired  marketed generics as well as three others which are close to market for  million from teva pharmaceutical industries operationsedit impax generics includes the company’s legacy global pharmaceuticals business as well as the acquired corepharma and lineage therapeutics businesses impax specialty pharma includes the legacy impax pharmaceuticals business as well as the acquired amedra pharmaceuticals business impax’s generics division focuses on a broad range of therapeutic areas including products having technically challenging drugdelivery mechanisms or unique product formulations in addition to developing solid oral dosage products the company’s portfolio includes alternative dosage form products primarily through alliance and collaboration agreements with third parties the company’s specialty pharma division is focused on the development and promotion through the company’s specialty sales force of proprietary branded pharmaceutical products for the treatment of central nervous system disorders and other select specialty segments the impax specialty pharma division currently has one internally developed branded pharmaceutical product rytary ipx an extended release oral capsule formulation of carbidopalevodopa for the treatment of parkinson’s disease postencephalitic parkinsonism and parkinsonism that may follow carbon monoxide intoxication andor manganese intoxication which was approved by the fda on january   regulatory and litigationedit several wholesale lots of impaxs  mg fenofibrate capsules were recalled in march  impax and dava pharmaceuticals engaged in a legal dispute with purdue pharma over the patents and production of timereleased oxycodone oxycontin until reaching an agreement in april  another dispute with endo pharmaceuticals and penwest pharmaceuticals concluded with impax gaining the right to begin producing extendedrelease oxymorphone through its global pharmaceuticals division as of  impax announced the resolution of its fda warning letter for its hayward ca facility on september   referencesedit use yyyymmdd format for publication dates  a b c d impax  annual report pdf   impax laboratories inc  investor relations  investor faq   our story  impax laboratories inc   impax march   press release impax completes acquisition of tower holdings inc and lineage therapeutics inc  impax buys generic product portfolio from teva allergan for m  gen news highlights  gen   teva sells castoffs to impax for m as clock ticks on allergan deal  fiercepharma   impax completes acquisition of tower holdings inc and lineage therapeutics inc press release hayward california impax laboratories inc    impax pharmaceuticals announce fda approval of rytary carbidopa and levodopa extendedrelease capsules for the treatment of parkinsons disease press release hayward california impax laboratories inc    warning letter inspections compliance enforcement and criminal investigations food and drug administration  archived from the original on  retrieved    miller george  impax reveals warning letter related to drug recall read more impax reveals warning letter related to drug recall fiercepharma manufacturing questex media group archived from the original on  retrieved    purdue pharma lp announces agreement to end oxycontin® patent lawsuit with impax laboratories press release purdue pharma  archived from the original on  retrieved    impax labs introduces oxymorphone hydrochloride extendedrelease tablets rttnews  archived from the original on  retrieved    larson erik  purdue impax settle oxycontin litigation law lexisnexis retrieved  registration required  impax announces resolution of fda warning letter related to its hayward manufacturing facility pdf press release hayward california impax laboratories inc   external linksedit official site retrieved from httpsenwikipediaorgwindexphptitleimpaxlaboratoriesoldid categories pharmaceutical companies of the united statescompanies based in hayward californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories pages with login required references or sourcespages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view impax laboratories  wikipedia impax laboratories from wikipedia the free encyclopedia jump to navigation search impax laboratories inc traded as nasdaq ipxl sp  component founded   founder charles hsiao phd and chungchiang hsu phd headquarters hayward california number of locations manufacturing plants in hayward ca middlesex nj and taiwan products generic and specialty pharmaceuticals revenue est  million  number of employees over  employees worldwide divisions generics and specialty pharma divisions website impaxlabscom impax laboratories inc is a publicly traded company listed on the nasdaq stock market llc under the symbol “ipxl” is a specialty pharmaceutical company focused on developing manufacturing and marketing generic and branded products the company is headquartered in hayward california and has additional offices and facilities in new jersey pennsylvania and taiwan roc contents  history  mergers and acquisitions  operations  regulatory and litigation  references  external links historyedit the company’s predecessor entity privately held impax pharmaceuticals inc was founded in  publicly traded global pharmaceutical corporation and impax pharmaceuticals inc completed a reverse merger forming impax laboratories inc on december   the merger combined the advanced drug delivery systems developed by impax pharmaceuticals through its research and development capabilities with global pharmaceutical’s sales marketing and distribution capabilities mergers and acquisitionsedit in march  impax completed its acquisition of tower holdings inc including operating subsidiaries corepharma llc and amedra pharmaceuticals llc including its adrenaclick epinephrine autoinjector and lineage therapeutics inc in connection with the closing of the acquisition impax reshaped the operating and reporting structure of its two divisions into impax generics and impax specialty pharma in june  the company acquired  marketed generics as well as three others which are close to market for  million from teva pharmaceutical industries operationsedit impax generics includes the company’s legacy global pharmaceuticals business as well as the acquired corepharma and lineage therapeutics businesses impax specialty pharma includes the legacy impax pharmaceuticals business as well as the acquired amedra pharmaceuticals business impax’s generics division focuses on a broad range of therapeutic areas including products having technically challenging drugdelivery mechanisms or unique product formulations in addition to developing solid oral dosage products the company’s portfolio includes alternative dosage form products primarily through alliance and collaboration agreements with third parties the company’s specialty pharma division is focused on the development and promotion through the company’s specialty sales force of proprietary branded pharmaceutical products for the treatment of central nervous system disorders and other select specialty segments the impax specialty pharma division currently has one internally developed branded pharmaceutical product rytary ipx an extended release oral capsule formulation of carbidopalevodopa for the treatment of parkinson’s disease postencephalitic parkinsonism and parkinsonism that may follow carbon monoxide intoxication andor manganese intoxication which was approved by the fda on january   regulatory and litigationedit several wholesale lots of impaxs  mg fenofibrate capsules were recalled in march  impax and dava pharmaceuticals engaged in a legal dispute with purdue pharma over the patents and production of timereleased oxycodone oxycontin until reaching an agreement in april  another dispute with endo pharmaceuticals and penwest pharmaceuticals concluded with impax gaining the right to begin producing extendedrelease oxymorphone through its global pharmaceuticals division as of  impax announced the resolution of its fda warning letter for its hayward ca facility on september   referencesedit use yyyymmdd format for publication dates  a b c d impax  annual report pdf   impax laboratories inc  investor relations  investor faq   our story  impax laboratories inc   impax march   press release impax completes acquisition of tower holdings inc and lineage therapeutics inc  impax buys generic product portfolio from teva allergan for m  gen news highlights  gen   teva sells castoffs to impax for m as clock ticks on allergan deal  fiercepharma   impax completes acquisition of tower holdings inc and lineage therapeutics inc press release hayward california impax laboratories inc    impax pharmaceuticals announce fda approval of rytary carbidopa and levodopa extendedrelease capsules for the treatment of parkinsons disease press release hayward california impax laboratories inc    warning letter inspections compliance enforcement and criminal investigations food and drug administration  archived from the original on  retrieved    miller george  impax reveals warning letter related to drug recall read more impax reveals warning letter related to drug recall fiercepharma manufacturing questex media group archived from the original on  retrieved    purdue pharma lp announces agreement to end oxycontin® patent lawsuit with impax laboratories press release purdue pharma  archived from the original on  retrieved    impax labs introduces oxymorphone hydrochloride extendedrelease tablets rttnews  archived from the original on  retrieved    larson erik  purdue impax settle oxycontin litigation law lexisnexis retrieved  registration required  impax announces resolution of fda warning letter related to its hayward manufacturing facility pdf press release hayward california impax laboratories inc   external linksedit official site retrieved from httpsenwikipediaorgwindexphptitleimpaxlaboratoriesoldid categories pharmaceutical companies of the united statescompanies based in hayward californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories pages with login required references or sourcespages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view impax laboratories  wikipedia impax laboratories from wikipedia the free encyclopedia jump to navigation search impax laboratories inc traded as nasdaq ipxl sp  component founded   founder charles hsiao phd and chungchiang hsu phd headquarters hayward california number of locations manufacturing plants in hayward ca middlesex nj and taiwan products generic and specialty pharmaceuticals revenue est  million  number of employees over  employees worldwide divisions generics and specialty pharma divisions website impaxlabscom impax laboratories inc is a publicly traded company listed on the nasdaq stock market llc under the symbol “ipxl” is a specialty pharmaceutical company focused on developing manufacturing and marketing generic and branded products the company is headquartered in hayward california and has additional offices and facilities in new jersey pennsylvania and taiwan roc contents  history  mergers and acquisitions  operations  regulatory and litigation  references  external links historyedit the company’s predecessor entity privately held impax pharmaceuticals inc was founded in  publicly traded global pharmaceutical corporation and impax pharmaceuticals inc completed a reverse merger forming impax laboratories inc on december   the merger combined the advanced drug delivery systems developed by impax pharmaceuticals through its research and development capabilities with global pharmaceutical’s sales marketing and distribution capabilities mergers and acquisitionsedit in march  impax completed its acquisition of tower holdings inc including operating subsidiaries corepharma llc and amedra pharmaceuticals llc including its adrenaclick epinephrine autoinjector and lineage therapeutics inc in connection with the closing of the acquisition impax reshaped the operating and reporting structure of its two divisions into impax generics and impax specialty pharma in june  the company acquired  marketed generics as well as three others which are close to market for  million from teva pharmaceutical industries operationsedit impax generics includes the company’s legacy global pharmaceuticals business as well as the acquired corepharma and lineage therapeutics businesses impax specialty pharma includes the legacy impax pharmaceuticals business as well as the acquired amedra pharmaceuticals business impax’s generics division focuses on a broad range of therapeutic areas including products having technically challenging drugdelivery mechanisms or unique product formulations in addition to developing solid oral dosage products the company’s portfolio includes alternative dosage form products primarily through alliance and collaboration agreements with third parties the company’s specialty pharma division is focused on the development and promotion through the company’s specialty sales force of proprietary branded pharmaceutical products for the treatment of central nervous system disorders and other select specialty segments the impax specialty pharma division currently has one internally developed branded pharmaceutical product rytary ipx an extended release oral capsule formulation of carbidopalevodopa for the treatment of parkinson’s disease postencephalitic parkinsonism and parkinsonism that may follow carbon monoxide intoxication andor manganese intoxication which was approved by the fda on january   regulatory and litigationedit several wholesale lots of impaxs  mg fenofibrate capsules were recalled in march  impax and dava pharmaceuticals engaged in a legal dispute with purdue pharma over the patents and production of timereleased oxycodone oxycontin until reaching an agreement in april  another dispute with endo pharmaceuticals and penwest pharmaceuticals concluded with impax gaining the right to begin producing extendedrelease oxymorphone through its global pharmaceuticals division as of  impax announced the resolution of its fda warning letter for its hayward ca facility on september   referencesedit use yyyymmdd format for publication dates  a b c d impax  annual report pdf   impax laboratories inc  investor relations  investor faq   our story  impax laboratories inc   impax march   press release impax completes acquisition of tower holdings inc and lineage therapeutics inc  impax buys generic product portfolio from teva allergan for m  gen news highlights  gen   teva sells castoffs to impax for m as clock ticks on allergan deal  fiercepharma   impax completes acquisition of tower holdings inc and lineage therapeutics inc press release hayward california impax laboratories inc    impax pharmaceuticals announce fda approval of rytary carbidopa and levodopa extendedrelease capsules for the treatment of parkinsons disease press release hayward california impax laboratories inc    warning letter inspections compliance enforcement and criminal investigations food and drug administration  archived from the original on  retrieved    miller george  impax reveals warning letter related to drug recall read more impax reveals warning letter related to drug recall fiercepharma manufacturing questex media group archived from the original on  retrieved    purdue pharma lp announces agreement to end oxycontin® patent lawsuit with impax laboratories press release purdue pharma  archived from the original on  retrieved    impax labs introduces oxymorphone hydrochloride extendedrelease tablets rttnews  archived from the original on  retrieved    larson erik  purdue impax settle oxycontin litigation law lexisnexis retrieved  registration required  impax announces resolution of fda warning letter related to its hayward manufacturing facility pdf press release hayward california impax laboratories inc   external linksedit official site retrieved from httpsenwikipediaorgwindexphptitleimpaxlaboratoriesoldid categories pharmaceutical companies of the united statescompanies based in hayward californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories pages with login required references or sourcespages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view impax laboratories  wikipedia impax laboratories from wikipedia the free encyclopedia jump to navigation search impax laboratories inc traded as nasdaq ipxl sp  component founded   founder charles hsiao phd and chungchiang hsu phd headquarters hayward california number of locations manufacturing plants in hayward ca middlesex nj and taiwan products generic and specialty pharmaceuticals revenue est  million  number of employees over  employees worldwide divisions generics and specialty pharma divisions website impaxlabscom impax laboratories inc is a publicly traded company listed on the nasdaq stock market llc under the symbol “ipxl” is a specialty pharmaceutical company focused on developing manufacturing and marketing generic and branded products the company is headquartered in hayward california and has additional offices and facilities in new jersey pennsylvania and taiwan roc contents  history  mergers and acquisitions  operations  regulatory and litigation  references  external links historyedit the company’s predecessor entity privately held impax pharmaceuticals inc was founded in  publicly traded global pharmaceutical corporation and impax pharmaceuticals inc completed a reverse merger forming impax laboratories inc on december   the merger combined the advanced drug delivery systems developed by impax pharmaceuticals through its research and development capabilities with global pharmaceutical’s sales marketing and distribution capabilities mergers and acquisitionsedit in march  impax completed its acquisition of tower holdings inc including operating subsidiaries corepharma llc and amedra pharmaceuticals llc including its adrenaclick epinephrine autoinjector and lineage therapeutics inc in connection with the closing of the acquisition impax reshaped the operating and reporting structure of its two divisions into impax generics and impax specialty pharma in june  the company acquired  marketed generics as well as three others which are close to market for  million from teva pharmaceutical industries operationsedit impax generics includes the company’s legacy global pharmaceuticals business as well as the acquired corepharma and lineage therapeutics businesses impax specialty pharma includes the legacy impax pharmaceuticals business as well as the acquired amedra pharmaceuticals business impax’s generics division focuses on a broad range of therapeutic areas including products having technically challenging drugdelivery mechanisms or unique product formulations in addition to developing solid oral dosage products the company’s portfolio includes alternative dosage form products primarily through alliance and collaboration agreements with third parties the company’s specialty pharma division is focused on the development and promotion through the company’s specialty sales force of proprietary branded pharmaceutical products for the treatment of central nervous system disorders and other select specialty segments the impax specialty pharma division currently has one internally developed branded pharmaceutical product rytary ipx an extended release oral capsule formulation of carbidopalevodopa for the treatment of parkinson’s disease postencephalitic parkinsonism and parkinsonism that may follow carbon monoxide intoxication andor manganese intoxication which was approved by the fda on january   regulatory and litigationedit several wholesale lots of impaxs  mg fenofibrate capsules were recalled in march  impax and dava pharmaceuticals engaged in a legal dispute with purdue pharma over the patents and production of timereleased oxycodone oxycontin until reaching an agreement in april  another dispute with endo pharmaceuticals and penwest pharmaceuticals concluded with impax gaining the right to begin producing extendedrelease oxymorphone through its global pharmaceuticals division as of  impax announced the resolution of its fda warning letter for its hayward ca facility on september   referencesedit use yyyymmdd format for publication dates  a b c d impax  annual report pdf   impax laboratories inc  investor relations  investor faq   our story  impax laboratories inc   impax march   press release impax completes acquisition of tower holdings inc and lineage therapeutics inc  impax buys generic product portfolio from teva allergan for m  gen news highlights  gen   teva sells castoffs to impax for m as clock ticks on allergan deal  fiercepharma   impax completes acquisition of tower holdings inc and lineage therapeutics inc press release hayward california impax laboratories inc    impax pharmaceuticals announce fda approval of rytary carbidopa and levodopa extendedrelease capsules for the treatment of parkinsons disease press release hayward california impax laboratories inc    warning letter inspections compliance enforcement and criminal investigations food and drug administration  archived from the original on  retrieved    miller george  impax reveals warning letter related to drug recall read more impax reveals warning letter related to drug recall fiercepharma manufacturing questex media group archived from the original on  retrieved    purdue pharma lp announces agreement to end oxycontin® patent lawsuit with impax laboratories press release purdue pharma  archived from the original on  retrieved    impax labs introduces oxymorphone hydrochloride extendedrelease tablets rttnews  archived from the original on  retrieved    larson erik  purdue impax settle oxycontin litigation law lexisnexis retrieved  registration required  impax announces resolution of fda warning letter related to its hayward manufacturing facility pdf press release hayward california impax laboratories inc   external linksedit official site retrieved from httpsenwikipediaorgwindexphptitleimpaxlaboratoriesoldid categories pharmaceutical companies of the united statescompanies based in hayward californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories pages with login required references or sourcespages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view impax laboratories  wikipedia impax laboratories from wikipedia the free encyclopedia jump to navigation search impax laboratories inc traded as nasdaq ipxl sp  component founded   founder charles hsiao phd and chungchiang hsu phd headquarters hayward california number of locations manufacturing plants in hayward ca middlesex nj and taiwan products generic and specialty pharmaceuticals revenue est  million  number of employees over  employees worldwide divisions generics and specialty pharma divisions website impaxlabscom impax laboratories inc is a publicly traded company listed on the nasdaq stock market llc under the symbol “ipxl” is a specialty pharmaceutical company focused on developing manufacturing and marketing generic and branded products the company is headquartered in hayward california and has additional offices and facilities in new jersey pennsylvania and taiwan roc contents  history  mergers and acquisitions  operations  regulatory and litigation  references  external links historyedit the company’s predecessor entity privately held impax pharmaceuticals inc was founded in  publicly traded global pharmaceutical corporation and impax pharmaceuticals inc completed a reverse merger forming impax laboratories inc on december   the merger combined the advanced drug delivery systems developed by impax pharmaceuticals through its research and development capabilities with global pharmaceutical’s sales marketing and distribution capabilities mergers and acquisitionsedit in march  impax completed its acquisition of tower holdings inc including operating subsidiaries corepharma llc and amedra pharmaceuticals llc including its adrenaclick epinephrine autoinjector and lineage therapeutics inc in connection with the closing of the acquisition impax reshaped the operating and reporting structure of its two divisions into impax generics and impax specialty pharma in june  the company acquired  marketed generics as well as three others which are close to market for  million from teva pharmaceutical industries operationsedit impax generics includes the company’s legacy global pharmaceuticals business as well as the acquired corepharma and lineage therapeutics businesses impax specialty pharma includes the legacy impax pharmaceuticals business as well as the acquired amedra pharmaceuticals business impax’s generics division focuses on a broad range of therapeutic areas including products having technically challenging drugdelivery mechanisms or unique product formulations in addition to developing solid oral dosage products the company’s portfolio includes alternative dosage form products primarily through alliance and collaboration agreements with third parties the company’s specialty pharma division is focused on the development and promotion through the company’s specialty sales force of proprietary branded pharmaceutical products for the treatment of central nervous system disorders and other select specialty segments the impax specialty pharma division currently has one internally developed branded pharmaceutical product rytary ipx an extended release oral capsule formulation of carbidopalevodopa for the treatment of parkinson’s disease postencephalitic parkinsonism and parkinsonism that may follow carbon monoxide intoxication andor manganese intoxication which was approved by the fda on january   regulatory and litigationedit several wholesale lots of impaxs  mg fenofibrate capsules were recalled in march  impax and dava pharmaceuticals engaged in a legal dispute with purdue pharma over the patents and production of timereleased oxycodone oxycontin until reaching an agreement in april  another dispute with endo pharmaceuticals and penwest pharmaceuticals concluded with impax gaining the right to begin producing extendedrelease oxymorphone through its global pharmaceuticals division as of  impax announced the resolution of its fda warning letter for its hayward ca facility on september   referencesedit use yyyymmdd format for publication dates  a b c d impax  annual report pdf   impax laboratories inc  investor relations  investor faq   our story  impax laboratories inc   impax march   press release impax completes acquisition of tower holdings inc and lineage therapeutics inc  impax buys generic product portfolio from teva allergan for m  gen news highlights  gen   teva sells castoffs to impax for m as clock ticks on allergan deal  fiercepharma   impax completes acquisition of tower holdings inc and lineage therapeutics inc press release hayward california impax laboratories inc    impax pharmaceuticals announce fda approval of rytary carbidopa and levodopa extendedrelease capsules for the treatment of parkinsons disease press release hayward california impax laboratories inc    warning letter inspections compliance enforcement and criminal investigations food and drug administration  archived from the original on  retrieved    miller george  impax reveals warning letter related to drug recall read more impax reveals warning letter related to drug recall fiercepharma manufacturing questex media group archived from the original on  retrieved    purdue pharma lp announces agreement to end oxycontin® patent lawsuit with impax laboratories press release purdue pharma  archived from the original on  retrieved    impax labs introduces oxymorphone hydrochloride extendedrelease tablets rttnews  archived from the original on  retrieved    larson erik  purdue impax settle oxycontin litigation law lexisnexis retrieved  registration required  impax announces resolution of fda warning letter related to its hayward manufacturing facility pdf press release hayward california impax laboratories inc   external linksedit official site retrieved from httpsenwikipediaorgwindexphptitleimpaxlaboratoriesoldid categories pharmaceutical companies of the united statescompanies based in hayward californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories pages with login required references or sourcespages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view impax laboratories inc  ipxl  stock price today  zacks quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  b dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date bmo prior year eps  exp eps growth yr forward pe  peg ratio  medical » medical  generic drugs bmo  before market open amc  after market close zacks earnings esp expected surprise prediction looks to find earnings surprises by focusing on the most recent analyst revisions this is done because generally speaking if an analyst reevaluates their earnings estimate right before an earnings release it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago the crux of this approach is comparing the most accurate estimate to the zacks consensus estimate although the zacks rank is also an important feature of the esp metric combining these two can help investors find stocks that are ready to beat the consensus at their next report and hopefully surge higher in price too in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time and best of all by using these parameters investors have seen  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research reports for ipxl     all zacks’ analyst reports premium research for ipxl zacks rank hold  zacks industry rank bottom  out of  zacks sector rank bottom   out of  style scores b value  b growth  c momentum  a vgm earnings esp  research reports for ipxl analyst  snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find earnings surprises by focusing on the most recent analyst revisions this is done because generally speaking if an analyst reevaluates their earnings estimate right before an earnings release it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago the crux of this approach is comparing the most accurate estimate to the zacks consensus estimate although the zacks rank is also an important feature of the esp metric combining these two can help investors find stocks that are ready to beat the consensus at their next report and hopefully surge higher in price too in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time and best of all by using these parameters investors have seen  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank impax laboratories inc ipxl aspen pharmacr apnhy acura pharmaceuticals inc acur adamas pharmaceuticals inc adms akorn inc akrx allergan plc agn amphastar pharmaceuticals inc amph see all medical  generic drugs peers zacks news for ipxl adamis gets fda nod for generic version of mylans epipen am est zacks why is impax ipxl down  since the last earnings report am est zacks ipxl what are zacks experts saying now zacks private portfolio services astrazeneca azn divests migraine drug rights beyond japan am est zacks impax ipxl q earnings miss stock up on cost savings plan am est zacks generic drugmakers tumble as perrigo discloses doj search am est zacks company summary impax laboratories inc is a technologybased specialty pharmaceutical company engaged in the development manufacture and marketing of specialty prescription pharmaceutical products utilizing its own formulation expertise and drug delivery technologies impax laboratories is focusing on two key areas namely generic pharmaceutical products and branded pharmaceutical products in the generic pharmaceuticals market it focuses its efforts on controlledrelease generic versions of selected brandname pharmaceuticals covering a range of therapeutic areas in the brandname pharmaceuticals market impax is developing products for the treatment of central nervous system disorders the company sells its products to large pharmaceutical wholesalers warehousing chain drug stores mass merchandisers and mailorder pharmacies through strategic alliances and the companys global pharmaceuticals division impax laboratories inc private company information  bloomberg july    pm et pharmaceuticals company overview of impax laboratories inc snapshot people company overview impax laboratories inc a specialty pharmaceutical company develops manufactures and markets bioequivalent pharmaceutical products it operates in two segments impax generics and impax specialty pharma the impax generics segment provides generic pharmaceutical products directly to wholesalers retail drug chains and others generic prescription products through thirdparty pharmaceutical entities pursuant to alliance agreements generic pharmaceutical overthecounter otc and prescription products to third parties and generic pharmaceutical otc products through thirdparty pharmaceutical companies pursuant to alliance agreements the impax specialty pharma segment focuses on the d impax laboratories inc a specialty pharmaceutical company develops manufactures and markets bioequivalent pharmaceutical products it operates in two segments impax generics and impax specialty pharma the impax generics segment provides generic pharmaceutical products directly to wholesalers retail drug chains and others generic prescription products through thirdparty pharmaceutical entities pursuant to alliance agreements generic pharmaceutical overthecounter otc and prescription products to third parties and generic pharmaceutical otc products through thirdparty pharmaceutical companies pursuant to alliance agreements the impax specialty pharma segment focuses on the development sale and distribution through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders including migraine multiple sclerosis parkinson’s disease and postherpetic neuralgia as well as other select specialty segments the company markets and sells its products to drug wholesalers warehousing chain drug stores mass merchandisers and mailorder pharmacies in the continental united states and the commonwealth of puerto rico impax laboratories inc has a strategic alliance agreement with teva pharmaceuticals usa inc to develop manufacture and distribute controlled release generic pharmaceutical products the company was founded in  and is headquartered in hayward california detailed description  huntwood avenuehayward ca united statesfounded in  employees phone  fax  wwwimpaxlabscom key executives for impax laboratories inc mr bryan m reasons chief financial officer and senior vice president of finance age  total annual compensation k mr michael j nestor president of impax specialty pharma division age  total annual compensation k mr douglas s boothe president of impax generics division age  total annual compensation k mr mark a schlossberg esq senior vice president general counsel and corporate secretary age  total annual compensation k mr jeffrey d nornhold senior vice president of technical operations age  total annual compensation m compensation as of fiscal year  impax laboratories inc key developments impax laboratories gets fda approval for generic concerta extendedrelease tablets jul   impax laboratories announced it received an ab therapeutic equivalent rating and final us food and drug administration approval on its abbreviated new drug application for a generic version of concerta extendedrelease tablets usp cii    and  mg it is preparing for launch including working to secure api quota and currently expect to launch by the end of  impax laboratories inc announces fda approval and launch of additional strengths of generic focalin xr® dexmethylphenidate hydrochloride extendedrelease capsules cii jul   impax laboratories inc announced it has received final us food and drug administration approval on its abbreviated new drug application anda for a generic version of focalin xr® dexmethylphenidate hydrochloride extendedrelease capsules cii  and  mg impax has immediately initiated commercialization activities this approval and launch of the  and  mg strengths complements the companys commercialized generic portfolio of focalin xr products which also includes strengths of     and  mg capsules according to ims health dexmethylphenidate hydrochloride extendedrelease capsules  and  mg had us brand and generic sales of approximately  million for the  months ending may  dexmethylphenidate hydrochloride extendedrelease capsules are indicated for the treatment of attention deficit hyperactivity disorder adhd in patients aged  years and older impax laboratories inc presents at goldman sachs th annual global healthcare conference jun  pm jun   impax laboratories inc presents at goldman sachs th annual global healthcare conference jun  pm venue terranea rancho palos verdes rancho palos verdes california united states speakers bryan m reasons chief financial officer and senior vice president of finance similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target mergeracquisition july   teva pharmaceutical industries limited rights and assets related to  pharmaceutical products request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states bertelsmann ag europe the advertising council inc united states rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact impax laboratories inc please visit wwwimpaxlabscom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close impax laboratories inc  impax laboratories announces leadership transition investor relations  media center  careers  contact homeour companyour experienceour divisionsmedia center media center media center media center press releases download library media centerpress releasesdownload librarymedia center home»media center»press releases»press release press release  back impax laboratories announces leadership transition  download this press release pdf  j kevin buchi appointed interim president and chief executive officer following departure of g frederick wilkinson  impax board commences search for permanent president and ceo  hayward calif dec   prnewswire  impax laboratories inc nasdaq ipxl today announced that j kevin buchi a member of the impax board of directors the board has been appointed interim president and chief executive officer the companys board has come to a mutual agreement with g frederick wilkinson that mr wilkinson separate from his positions as president and chief executive officer and as a member of the board effective immediately logo  httpphotosprnewswirecomprnhlogo the nominating committee of the impax board has initiated a search to identify a permanent president and chief executive officer fred has been instrumental in impaxs ability to remove the warning letter regarding the companys hayward facility which has allowed us to regain generic approvals from that facility said robert l burr chairman of the board of directors of impax laboratories additionally we appreciate his contributions in helping to get rytary® approved and launched and enhancing the companys generic and brand portfolio with the acquisition of the tower entities on behalf of the board we wish him well in his future endeavors mr burr added the board of directors remains confident in and committed to the companys strategic direction we are focused on finding a successor ceo that will lead impax through its future growth until then kevin who brings a great deal of pharmaceutical experience along with a highly experienced executive management team will lead the company i am extremely proud of the many accomplishments impax has realized over the past several years said mr wilkinson i am truly grateful for the support ive received from the board of directors the executive management team and most importantly our highly dedicated employees i am confident that impax is well positioned for great success in the future mr buchi said i look forward to working closely with the impax board and management team in this interim role together we will ensure a smooth transition to impaxs next ceo and will remain focused on our corporate priorities and continue to execute on our core competencies in drug delivery formulation technology and product development about j kevin buchi mr buchi currently serves as president chief executive officer and a member of the board of directors of tetralogic pharmaceuticals corporation  mr buchi intends to retire from his position as president and chief executive officer of tetralogic pharmaceuticals at the end of the year commensurate with tetralogic pharmaceuticals previously announced asset sale to medivir ab which transaction is currently expected to close by december    prior to joining tetralogic pharmaceuticals in august  mr buchi served as corporate vice president of global branded products at teva pharmaceutical industries limited from  to may  before joining teva he was chief executive officer of cephalon inc which was acquired by teva in october  mr buchi joined cephalon in  and held various leadership positions including chief financial officer and chief operating officer before becoming cephalons chief executive officer in december  in addition to serving as a director of impax and tetralogic pharmaceuticals mr buchi has since  served as a director of benitec biopharma ltd a nasdaq listed biotechnology company headquartered in australia he has extensive experience as a director having previously served on the board of a number of pharmaceutical companies including epirus biopharmaceuticals inc alexza pharmaceuticals inc and forward pharma as mr buchi received his ba degree in chemistry from cornell university and a masters of management degree from the jl kellogg graduate school of management northwestern university safe harbor statement under the private securities litigation reform act of  to the extent any statements made in this news release contain information that is not historical these statements are forwardlooking in nature and express the beliefs and expectations of management such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the companys future results performance or achievements to differ significantly from the results performance or achievements expressed or implied by such forwardlooking statements such risks and uncertainties include but are not limited to fluctuations in revenues and operating income the companys ability to successfully develop and commercialize pharmaceutical products in a timely manner reductions or loss of business with any significant customer the substantial portion of the companys total revenues derived from sales of a limited number of products the impact of consolidation of the companys customer base the impact of competition the companys ability to sustain profitability and positive cash flows any delays or unanticipated expenses in connection with the operation of the companys manufacturing facilities the effect of foreign economic political legal and other risks on the companys operations abroad the uncertainty of patent litigation and other legal proceedings the increased government scrutiny on the companys agreements with brand pharmaceutical companies product development risks and the difficulty of predicting fda filings and approvals consumer acceptance and demand for new pharmaceutical products the impact of market perceptions of the company and the safety and quality of the companys products the companys determinations to discontinue the manufacture and distribution of certain products the companys ability to achieve returns on its investments in research and development activities changes to fda approval requirements the companys ability to successfully conduct clinical trials the companys reliance on third parties to conduct clinical trials and testing the companys lack of a license partner for commercialization of numient™ ipx outside of the united states impact of illegal distribution and sale by third parties of counterfeits or stolen products the availability of raw materials and impact of interruptions in the companys supply chain the companys policies regarding returns allowances and chargebacks the use of controlled substances in the companys products the effect of current economic conditions on the companys  industry business results of operations and financial condition disruptions or failures in the companys information technology systems and network infrastructure caused by third party breaches or other events the companys reliance on alliance and collaboration agreements the companys reliance on licenses to proprietary technologies the companys dependence on certain employees the companys ability to comply with legal and regulatory requirements governing the healthcare industry the regulatory environment the effect of certain provisions in the companys government contracts the companys ability to protect its intellectual property exposure to product liability claims risks relating to goodwill and intangibles changes in tax regulations the companys ability to manage growth including through potential acquisitions and investments  the risks related to the companys acquisitions of or investments in technologies products or businesses the restrictions imposed by the companys credit facility and indenture the companys level of indebtedness and liabilities and the potential impact  on cash flow available for operations uncertainties involved in the preparation of the companys financial statements the companys ability to maintain an effective system of internal control over financial reporting the effect of terrorist attacks on the companys business the location of the companys manufacturing and research and development facilities near earthquake fault lines expansion of social media platforms and other risks described in the companys periodic reports filed with the securities and exchange commission forwardlooking statements speak only as to the date on which they are made and the company undertakes no obligation to update publicly or revise any forwardlooking statement regardless of whether new information becomes available future developments occur or otherwise about impax laboratories inc impax laboratories inc impax is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlledrelease and specialty generics in addition to the development of central nervous system disorder branded products impax markets its generic products through its impax generics division and markets its branded products through its impax specialty pharma division additionally where strategically appropriate impax develops marketing partnerships to fully leverage its technology platforms and pursues partnership opportunities that offer alternative dosage form technologies such as injectables nasal sprays inhalers patches creams and ointments for more information please visit the companys web site at wwwimpaxlabscom company contacts mark donohue investor relations and corporate communications     wwwimpaxlabscom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesimpaxlaboratoriesannouncesleadershiptransitionhtml source impax laboratories inc related links products and pipeline leadership contact investor toolkit email page rss feeds email alerts copyright   impax laboratories inc all rights reserved sitemap  legal and copyright disclaimer name first name is required email email is required comments enter text   enter the code shown above  invalid powered by q inc  products  impax pharmaceuticals investor relations news careers contact impax laboratories impax pharmaceuticals home about us rd focus products business development products customers home » products impax pharmaceuticals commercialization  sales committed to improving patient lives through advancing knowledge of treatments for neurological disorders since inception in july  impax pharmaceuticals commercial organization has established a leading presence within the neurology community impax deploys approximately  field personnel determined to further enhance and solidify long standing relationships with over  neurologists in the us impax has adopted a customer focused orientation towards all commercial interactions in that relation we strive to first understand customer informational needs relative to our products and then responsibly offer solutions intended to satisfy that expressed need this requires a highly competent educated and welltrained field organization with the presence of mind to appropriately address customer concerns current products treatments for cns disorders to learn more about rytary™ visit wwwrytarycom prescribing information to learn more about zomig® visit wwwzomigcom prescribing information other specialty products to learn more about albenza® visit wwwalbenzacom to learn more about emverm™ visit wwwemvermcom prescribing information top related linksproduct pipeline  impax pharmaceuticals  all rights reserved home contact privacy policy legal notices sitemap contact  impax pharmaceuticals investor relations news careers contact impax laboratories impax pharmaceuticals home about us rd focus products business development home » contact contact impax pharmaceuticals a division of impax laboratories inc  genstar road hayward ca  phone   to report suspected adverse reactions product complaints or for medical information please contact phone impax  option  phone   option       or email inquiriesimpaxlabscom      or  genstar road hayward ca  attention medical affairs you are encouraged to report negative side effects of prescription drugs to the fda visit wwwfdagovmedwatch or call fda for customer service related questions product orders delivery billing account etc please contact phone impax  option      or email customerservicegroupglobalpharcom for investor information email investimpaxlabscom related linksabout us  impax pharmaceuticals  all rights reserved home contact privacy policy legal notices sitemap microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft impax laboratories ipxl  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in impax laboratories inc ipxl  last  days median target price   upside positive ratings  of  analysts latest  piper jaffray  neutral     view all analyst ratings for ipxl » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » home  impax laboratories inc investor relations media center careers contact home our company our experience our divisions learn more improving health through technology impax laboratories is a technologybased specialty pharmaceutical company a leader in the development manufacturing and marketing of specialty prescription pharmaceutical products a dual strategic focus our generics division global pharmaceuticals develops controlledrelease and specialty generics our branded products division impax pharmaceuticals specializes in developing products for the treatment of central nervous system disorders experience is our strength our drug delivery technologies are the foundation of our strength as a company latest news mon  jul impax announces fda approval of its ab rated generic concerta® methylphenidate hydrochloride extendedrelease tablets ciiwed  jul impax announces fda approval and launch of additional strengths of generic focalin xr® dexmethylphenidate hydrochloride extendedrelease capsules ciithu  jun impax to report second quarter  results on august  view all featured generic product epinephrine injection usp autoinjector  mg and  mg authorized generic to adrenaclick® link to prescribing information including all warnings view product featured specialty pharma product rytary carbidopa and levodopa extendedrelease capsules link to prescribing information including all warnings view product copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap impax laboratories  wikipedia impax laboratories from wikipedia the free encyclopedia jump to navigation search impax laboratories inc traded as nasdaq ipxl sp  component founded   founder charles hsiao phd and chungchiang hsu phd headquarters hayward california number of locations manufacturing plants in hayward ca middlesex nj and taiwan products generic and specialty pharmaceuticals revenue est  million  number of employees over  employees worldwide divisions generics and specialty pharma divisions website impaxlabscom impax laboratories inc is a publicly traded company listed on the nasdaq stock market llc under the symbol “ipxl” is a specialty pharmaceutical company focused on developing manufacturing and marketing generic and branded products the company is headquartered in hayward california and has additional offices and facilities in new jersey pennsylvania and taiwan roc contents  history  mergers and acquisitions  operations  regulatory and litigation  references  external links historyedit the company’s predecessor entity privately held impax pharmaceuticals inc was founded in  publicly traded global pharmaceutical corporation and impax pharmaceuticals inc completed a reverse merger forming impax laboratories inc on december   the merger combined the advanced drug delivery systems developed by impax pharmaceuticals through its research and development capabilities with global pharmaceutical’s sales marketing and distribution capabilities mergers and acquisitionsedit in march  impax completed its acquisition of tower holdings inc including operating subsidiaries corepharma llc and amedra pharmaceuticals llc including its adrenaclick epinephrine autoinjector and lineage therapeutics inc in connection with the closing of the acquisition impax reshaped the operating and reporting structure of its two divisions into impax generics and impax specialty pharma in june  the company acquired  marketed generics as well as three others which are close to market for  million from teva pharmaceutical industries operationsedit impax generics includes the company’s legacy global pharmaceuticals business as well as the acquired corepharma and lineage therapeutics businesses impax specialty pharma includes the legacy impax pharmaceuticals business as well as the acquired amedra pharmaceuticals business impax’s generics division focuses on a broad range of therapeutic areas including products having technically challenging drugdelivery mechanisms or unique product formulations in addition to developing solid oral dosage products the company’s portfolio includes alternative dosage form products primarily through alliance and collaboration agreements with third parties the company’s specialty pharma division is focused on the development and promotion through the company’s specialty sales force of proprietary branded pharmaceutical products for the treatment of central nervous system disorders and other select specialty segments the impax specialty pharma division currently has one internally developed branded pharmaceutical product rytary ipx an extended release oral capsule formulation of carbidopalevodopa for the treatment of parkinson’s disease postencephalitic parkinsonism and parkinsonism that may follow carbon monoxide intoxication andor manganese intoxication which was approved by the fda on january   regulatory and litigationedit several wholesale lots of impaxs  mg fenofibrate capsules were recalled in march  impax and dava pharmaceuticals engaged in a legal dispute with purdue pharma over the patents and production of timereleased oxycodone oxycontin until reaching an agreement in april  another dispute with endo pharmaceuticals and penwest pharmaceuticals concluded with impax gaining the right to begin producing extendedrelease oxymorphone through its global pharmaceuticals division as of  impax announced the resolution of its fda warning letter for its hayward ca facility on september   referencesedit use yyyymmdd format for publication dates  a b c d impax  annual report pdf   impax laboratories inc  investor relations  investor faq   our story  impax laboratories inc   impax march   press release impax completes acquisition of tower holdings inc and lineage therapeutics inc  impax buys generic product portfolio from teva allergan for m  gen news highlights  gen   teva sells castoffs to impax for m as clock ticks on allergan deal  fiercepharma   impax completes acquisition of tower holdings inc and lineage therapeutics inc press release hayward california impax laboratories inc    impax pharmaceuticals announce fda approval of rytary carbidopa and levodopa extendedrelease capsules for the treatment of parkinsons disease press release hayward california impax laboratories inc    warning letter inspections compliance enforcement and criminal investigations food and drug administration  archived from the original on  retrieved    miller george  impax reveals warning letter related to drug recall read more impax reveals warning letter related to drug recall fiercepharma manufacturing questex media group archived from the original on  retrieved    purdue pharma lp announces agreement to end oxycontin® patent lawsuit with impax laboratories press release purdue pharma  archived from the original on  retrieved    impax labs introduces oxymorphone hydrochloride extendedrelease tablets rttnews  archived from the original on  retrieved    larson erik  purdue impax settle oxycontin litigation law lexisnexis retrieved  registration required  impax announces resolution of fda warning letter related to its hayward manufacturing facility pdf press release hayward california impax laboratories inc   external linksedit official site retrieved from httpsenwikipediaorgwindexphptitleimpaxlaboratoriesoldid categories pharmaceutical companies of the united statescompanies based in hayward californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories pages with login required references or sourcespages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی     한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info home  impax laboratories inc investor relations media center careers contact home our company our experience our divisions learn more improving health through technology impax laboratories is a technologybased specialty pharmaceutical company a leader in the development manufacturing and marketing of specialty prescription pharmaceutical products a dual strategic focus our generics division global pharmaceuticals develops controlledrelease and specialty generics our branded products division impax pharmaceuticals specializes in developing products for the treatment of central nervous system disorders experience is our strength our drug delivery technologies are the foundation of our strength as a company latest news mon  jul impax announces fda approval of its ab rated generic concerta® methylphenidate hydrochloride extendedrelease tablets ciiwed  jul impax announces fda approval and launch of additional strengths of generic focalin xr® dexmethylphenidate hydrochloride extendedrelease capsules ciithu  jun impax to report second quarter  results on august  view all featured generic product epinephrine injection usp autoinjector  mg and  mg authorized generic to adrenaclick® link to prescribing information including all warnings view product featured specialty pharma product rytary carbidopa and levodopa extendedrelease capsules link to prescribing information including all warnings view product copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap impax laboratories  wikipedia impax laboratories from wikipedia the free encyclopedia jump to navigation search impax laboratories inc traded as nasdaq ipxl sp  component founded   founder charles hsiao phd and chungchiang hsu phd headquarters hayward california number of locations manufacturing plants in hayward ca middlesex nj and taiwan products generic and specialty pharmaceuticals revenue est  million  number of employees over  employees worldwide divisions generics and specialty pharma divisions website impaxlabscom impax laboratories inc is a publicly traded company listed on the nasdaq stock market llc under the symbol “ipxl” is a specialty pharmaceutical company focused on developing manufacturing and marketing generic and branded products the company is headquartered in hayward california and has additional offices and facilities in new jersey pennsylvania and taiwan roc contents  history  mergers and acquisitions  operations  regulatory and litigation  references  external links historyedit the company’s predecessor entity privately held impax pharmaceuticals inc was founded in  publicly traded global pharmaceutical corporation and impax pharmaceuticals inc completed a reverse merger forming impax laboratories inc on december   the merger combined the advanced drug delivery systems developed by impax pharmaceuticals through its research and development capabilities with global pharmaceutical’s sales marketing and distribution capabilities mergers and acquisitionsedit in march  impax completed its acquisition of tower holdings inc including operating subsidiaries corepharma llc and amedra pharmaceuticals llc including its adrenaclick epinephrine autoinjector and lineage therapeutics inc in connection with the closing of the acquisition impax reshaped the operating and reporting structure of its two divisions into impax generics and impax specialty pharma in june  the company acquired  marketed generics as well as three others which are close to market for  million from teva pharmaceutical industries operationsedit impax generics includes the company’s legacy global pharmaceuticals business as well as the acquired corepharma and lineage therapeutics businesses impax specialty pharma includes the legacy impax pharmaceuticals business as well as the acquired amedra pharmaceuticals business impax’s generics division focuses on a broad range of therapeutic areas including products having technically challenging drugdelivery mechanisms or unique product formulations in addition to developing solid oral dosage products the company’s portfolio includes alternative dosage form products primarily through alliance and collaboration agreements with third parties the company’s specialty pharma division is focused on the development and promotion through the company’s specialty sales force of proprietary branded pharmaceutical products for the treatment of central nervous system disorders and other select specialty segments the impax specialty pharma division currently has one internally developed branded pharmaceutical product rytary ipx an extended release oral capsule formulation of carbidopalevodopa for the treatment of parkinson’s disease postencephalitic parkinsonism and parkinsonism that may follow carbon monoxide intoxication andor manganese intoxication which was approved by the fda on january   regulatory and litigationedit several wholesale lots of impaxs  mg fenofibrate capsules were recalled in march  impax and dava pharmaceuticals engaged in a legal dispute with purdue pharma over the patents and production of timereleased oxycodone oxycontin until reaching an agreement in april  another dispute with endo pharmaceuticals and penwest pharmaceuticals concluded with impax gaining the right to begin producing extendedrelease oxymorphone through its global pharmaceuticals division as of  impax announced the resolution of its fda warning letter for its hayward ca facility on september   referencesedit use yyyymmdd format for publication dates  a b c d impax  annual report pdf   impax laboratories inc  investor relations  investor faq   our story  impax laboratories inc   impax march   press release impax completes acquisition of tower holdings inc and lineage therapeutics inc  impax buys generic product portfolio from teva allergan for m  gen news highlights  gen   teva sells castoffs to impax for m as clock ticks on allergan deal  fiercepharma   impax completes acquisition of tower holdings inc and lineage therapeutics inc press release hayward california impax laboratories inc    impax pharmaceuticals announce fda approval of rytary carbidopa and levodopa extendedrelease capsules for the treatment of parkinsons disease press release hayward california impax laboratories inc    warning letter inspections compliance enforcement and criminal investigations food and drug administration  archived from the original on  retrieved    miller george  impax reveals warning letter related to drug recall read more impax reveals warning letter related to drug recall fiercepharma manufacturing questex media group archived from the original on  retrieved    purdue pharma lp announces agreement to end oxycontin® patent lawsuit with impax laboratories press release purdue pharma  archived from the original on  retrieved    impax labs introduces oxymorphone hydrochloride extendedrelease tablets rttnews  archived from the original on  retrieved    larson erik  purdue impax settle oxycontin litigation law lexisnexis retrieved  registration required  impax announces resolution of fda warning letter related to its hayward manufacturing facility pdf press release hayward california impax laboratories inc   external linksedit official site retrieved from httpsenwikipediaorgwindexphptitleimpaxlaboratoriesoldid categories pharmaceutical companies of the united statescompanies based in hayward californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories pages with login required references or sourcespages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view impax laboratories  linkedin linkedin main content starts below impax laboratories  wikipedia impax laboratories from wikipedia the free encyclopedia jump to navigation search impax laboratories inc traded as nasdaq ipxl sp  component founded   founder charles hsiao phd and chungchiang hsu phd headquarters hayward california number of locations manufacturing plants in hayward ca middlesex nj and taiwan products generic and specialty pharmaceuticals revenue est  million  number of employees over  employees worldwide divisions generics and specialty pharma divisions website impaxlabscom impax laboratories inc is a publicly traded company listed on the nasdaq stock market llc under the symbol “ipxl” is a specialty pharmaceutical company focused on developing manufacturing and marketing generic and branded products the company is headquartered in hayward california and has additional offices and facilities in new jersey pennsylvania and taiwan roc contents  history  mergers and acquisitions  operations  regulatory and litigation  references  external links historyedit the company’s predecessor entity privately held impax pharmaceuticals inc was founded in  publicly traded global pharmaceutical corporation and impax pharmaceuticals inc completed a reverse merger forming impax laboratories inc on december   the merger combined the advanced drug delivery systems developed by impax pharmaceuticals through its research and development capabilities with global pharmaceutical’s sales marketing and distribution capabilities mergers and acquisitionsedit in march  impax completed its acquisition of tower holdings inc including operating subsidiaries corepharma llc and amedra pharmaceuticals llc including its adrenaclick epinephrine autoinjector and lineage therapeutics inc in connection with the closing of the acquisition impax reshaped the operating and reporting structure of its two divisions into impax generics and impax specialty pharma in june  the company acquired  marketed generics as well as three others which are close to market for  million from teva pharmaceutical industries operationsedit impax generics includes the company’s legacy global pharmaceuticals business as well as the acquired corepharma and lineage therapeutics businesses impax specialty pharma includes the legacy impax pharmaceuticals business as well as the acquired amedra pharmaceuticals business impax’s generics division focuses on a broad range of therapeutic areas including products having technically challenging drugdelivery mechanisms or unique product formulations in addition to developing solid oral dosage products the company’s portfolio includes alternative dosage form products primarily through alliance and collaboration agreements with third parties the company’s specialty pharma division is focused on the development and promotion through the company’s specialty sales force of proprietary branded pharmaceutical products for the treatment of central nervous system disorders and other select specialty segments the impax specialty pharma division currently has one internally developed branded pharmaceutical product rytary ipx an extended release oral capsule formulation of carbidopalevodopa for the treatment of parkinson’s disease postencephalitic parkinsonism and parkinsonism that may follow carbon monoxide intoxication andor manganese intoxication which was approved by the fda on january   regulatory and litigationedit several wholesale lots of impaxs  mg fenofibrate capsules were recalled in march  impax and dava pharmaceuticals engaged in a legal dispute with purdue pharma over the patents and production of timereleased oxycodone oxycontin until reaching an agreement in april  another dispute with endo pharmaceuticals and penwest pharmaceuticals concluded with impax gaining the right to begin producing extendedrelease oxymorphone through its global pharmaceuticals division as of  impax announced the resolution of its fda warning letter for its hayward ca facility on september   referencesedit use yyyymmdd format for publication dates  a b c d impax  annual report pdf   impax laboratories inc  investor relations  investor faq   our story  impax laboratories inc   impax march   press release impax completes acquisition of tower holdings inc and lineage therapeutics inc  impax buys generic product portfolio from teva allergan for m  gen news highlights  gen   teva sells castoffs to impax for m as clock ticks on allergan deal  fiercepharma   impax completes acquisition of tower holdings inc and lineage therapeutics inc press release hayward california impax laboratories inc    impax pharmaceuticals announce fda approval of rytary carbidopa and levodopa extendedrelease capsules for the treatment of parkinsons disease press release hayward california impax laboratories inc    warning letter inspections compliance enforcement and criminal investigations food and drug administration  archived from the original on  retrieved    miller george  impax reveals warning letter related to drug recall read more impax reveals warning letter related to drug recall fiercepharma manufacturing questex media group archived from the original on  retrieved    purdue pharma lp announces agreement to end oxycontin® patent lawsuit with impax laboratories press release purdue pharma  archived from the original on  retrieved    impax labs introduces oxymorphone hydrochloride extendedrelease tablets rttnews  archived from the original on  retrieved    larson erik  purdue impax settle oxycontin litigation law lexisnexis retrieved  registration required  impax announces resolution of fda warning letter related to its hayward manufacturing facility pdf press release hayward california impax laboratories inc   external linksedit official site retrieved from httpsenwikipediaorgwindexphptitleimpaxlaboratoriesoldid categories pharmaceutical companies of the united statescompanies based in hayward californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories pages with login required references or sourcespages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view